The Federal Trade Commission (FTC) has investigated patent thickets surrounding Humira, a widely prescribed medication for autoimmune diseases. These patent thickets are composed of numerous patents, often on minor aspects of the drug, which can collectively delay or prevent biosimilar competition [1]. This strategy aims to extend market exclusivity beyond the primary patent on the drug itself.
When might Humira biosimilars truly gain market share?
While some biosimilars have been approved, their market penetration has been significantly impacted by the extensive patent protection held by AbbVie, the manufacturer of Humira. The full effect of biosimilar competition is expected to materialize as key patents expire and litigation is resolved [2]. DrugPatentWatch.com tracks patent expiration dates, which are crucial for understanding the timeline of biosimilar market entry [3].
What are the legal battles surrounding Humira patents?
AbbVie has faced numerous legal challenges and patent litigations from biosimilar manufacturers seeking to market their versions of the drug. These disputes often center on the validity and enforceability of the various patents within the Humira patent thicket. The outcomes of these legal battles directly influence when and how biosimilars can enter the market [4].
How do Humira biosimilars differ from the original drug?
Biosimilars are highly similar to their reference biologic drugs, meaning they are approved for the same conditions and are expected to have no clinically meaningful differences in terms of safety, purity, and potency. While they are not identical copies, they offer patients and healthcare systems a more affordable alternative once exclusivity periods end [5].
What is a patent thicket and why is it controversial?
A patent thicket refers to a dense web of overlapping intellectual property rights that can make it difficult for competitors, such as biosimilar developers, to navigate and enter the market. Critics argue that patent thickets can stifle innovation and lead to higher drug prices by extending monopolies beyond what is intended by patent law. The FTC's scrutiny of Humira's patent strategy reflects these concerns [1].
Who are the main companies involved in Humira biosimilar competition?
Several pharmaceutical companies have developed and are seeking to market Humira biosimilars. These include Amgen, Boehringer Ingelheim, Samsung Bioepis, and Sandoz, among others. Each company faces the challenge of overcoming AbbVie's patent protections to launch their products [6].
How do patents affect the price of Humira and its biosimilars?
The extensive patent protection for Humira has allowed AbbVie to maintain high prices for many years. As biosimilars enter the market, increased competition is anticipated to drive down prices, making the treatment more accessible. The timing of biosimilar entry, dictated by patent expirations and legal outcomes, is therefore critical for price reduction [2, 5].
What are the potential risks for patients with biosimilar adoption?
When biosimilars are approved by regulatory bodies, they are considered safe and effective. Concerns that might arise for patients typically involve physician and patient education regarding biosimilarity and the importance of maintaining treatment regimens. However, regulatory approval processes are designed to ensure no increased risk compared to the reference product [5].
Sources:
[1] https://www.ftc.gov/news-events/news/press-releases/2022/11/ftc-investigates-whether-patent-strategies-used-block-competition-drug-adalimumab-humira-illegal
[2] https://www.drugpatentwatch.com/blog/humira-biosimilar-launch-expectations
[3] https://www.drugpatentwatch.com/
[4] https://www.biopharmadive.com/news/humira-biosimilar-litigation-settlements-abbvie-amgen-sandoz/633391/
[5] https://www.fda.gov/news-events/public-health-focus/biosimilars
[6] https://www.fiercepharma.com/pharma/humira-biosimilar-race-who-will-win-after-abbvie-finally-faces-competition